News
Under pressure, Novo lays out blockbuster launch plans
Novo has revealed a plan to launch five or more blockbusters between now and 2030 that it hopes will grow annual revenues by around $23bn.
News
Telix to buy radiopharma rival ITM for $1.65bn upfront
Telix Pharma has reached a deal to acquire ITM, extending a wave of consolidation in the radiopharma category over the last couple of years.
News
AZ's gMG drug Klygefa nears EU approval
AstraZeneca's generalised myasthenia gravis (gMG) therapy Klygefa gets CHMP recommendation, alongside several other novel medicines.
News
CHMP backs Novo's haemophilia A drug Frehemgo
Novo has moved a step closer to EU approval of its long-acting haemophilia A therapy, Frehemgo, which could be a future blockbuster.
News
Ultragenyx gets FDA nod for first Sanfilippo A gene therapy
Patients in the US with Sanfilippo syndrome type A have their first FDA-approved therapy, Ultragenyx Pharma's $3.9m one-shot gene therapy Fayuvi.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
